In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate ...

A novel presbyopia drop improves near vision using pupillary constriction to create a pinhole effect, while allowing good distance vision.

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, ...

“In our studies, brimonidine increased the magnitude and duration of action of carbachol and reduced the incidence of hyperemia (eye redness) over carbachol alone. BRIMOCHOL™ PF is the only presbyopia ...

Mid-stage presbyopia trials are also being run by Visus Therapeutics on Brimochol (carbachol and brimonidine tartrate) and LENZ Therapeutics on aceclidine. Novartis meanwhile is taking a different ...

Phentolamine acts as a pupil dilator. It's a similar approach to that taken by Visus Therapeutics with Brimochol – based on carbachol which acts like pilocarpine and brimonidine tartrate ...

The global mobile health (mHealth) apps and solutions market is projected to experience significant growth, with a compound annual growth rate (CAGR) of 18.18% ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.